Protocol for Scoping Review on Digital Patient Simulation Among Nursing Students
This publication represents a protocol for a scoping review rather than a completed study or meta-analysis. The planned scope focuses on the use of clinical simulation with digital patients within the context of nursing students. As a protocol, this document outlines the intended methodology but does not present data, findings, or conclusions from the review itself. It serves as a preliminary record of the research plan.
No primary or secondary outcomes are reported in this text. The sample size for the included studies within the scoping review is not reported, and no specific results regarding educational effectiveness or clinical performance are available. Safety data, including adverse events, discontinuations, and tolerability, are also not reported. Consequently, no pooled effect sizes or statistical analyses can be summarized from this source. The absence of numerical data prevents any quantitative assessment of the intervention.
The authors have not reported specific limitations regarding the protocol design or potential biases in the planned search strategy. Similarly, practice relevance is not reported, meaning clinical applicability cannot be assessed at this stage. Funding or conflicts of interest are not reported, which limits the ability to evaluate potential industry influence on the upcoming review. These missing details are standard for protocols but restrict immediate utility.
Clinicians should recognize that this document serves as a registration or planning statement for future evidence synthesis. It does not provide actionable clinical guidance or evidence-based recommendations at this time. Further updates will be required once the scoping review is completed and results are published to inform practice. Until then, the evidence base remains incomplete and uncertain for clinical decision-making.
View Original Abstract ↓
Mazdutide monotherapy reduces HbA1c and promotes weight loss in Chinese adults with type 2 diabetes over 48 weeks.
New Drug Lowers Sugar and Shrinks Weight in Diabetes
Related in Drug Pipeline
From Other Specialties
